laboratory diagnosis of antiphospholipid syndrome

Clicks: 192
ID: 252740
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #38 of 51 articles by views in advances in civil engineering

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Diagnosis of antiphosholipid syndrome (APS) is based on laboratory detection of antiphospholipid (aPL) antibodies in patients with documented thrombosis or in women with pregnancy morbidity. Recently, both clinical and laboratory criteria were revised on the basis of an international consensus conference held in Sydney (1). The previous international consensus statement of one clinical and one laboratory criterion to diagnose APS was maintained (2) but time-lapse between the previous thromboembolism and laboratory diagnosis should not exceed 5 years. Moreover, laboratory tests should not be performed in the 12 weeks following the event to avoid any interference of the acute phase of the disease. Thus, laboratory evaluation of venous thromboembolism (VTE) should not be requested during the hospital stay as tests may be false-positive with no influence on the treatment regimen...
Reference Key
ruffatti2011reumatismolaboratory Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;A. Ruffatti;V. Pengo
Journal advances in civil engineering
Year 2011
DOI
10.4081/reumatismo.2007.187
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.